



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 31/21, 31/04, 31/345</b>		<b>A1</b>	(11) International Publication Number: <b>WO 95/06466</b>
			(43) International Publication Date: 9 March 1995 (09.03.95)
(21) International Application Number: <b>PCT/AU94/00487</b>		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD).	
(22) International Filing Date: 19 August 1994 (19.08.94)			
(30) Priority Data: PM 0971 1 September 1993 (01.09.93) AU PM 4247 4 March 1994 (04.03.94) AU PM 6395 22 June 1994 (22.06.94) AU			
(71) Applicant (for all designated States except US): <b>KOREN LABORATORIES PTY. LIMITED [AU/AU]; 10 Cecil Street, Paddington, NSW 2011 (AU).</b>		Published <i>With international search report.</i>	
(72) Inventor; and (75) Inventor/Applicant (for US only): <b>LUBOWSKI, David [ZA/AU]; Second Floor, 22 Belgrave Street, Kogarah, NSW 2217 (AU).</b>			
(74) Agents: <b>STEARNE, Peter, Andrew et al.; Davies &amp; Collison, 1 Little Collins Street, Melbourne, VIC 3000 (AU).</b>			
(54) Title: <b>TREATMENT OF ANORECTAL DISORDERS</b>			
(57) Abstract  A method for the treatment of anorectal conditions in animals is described. The method involves administering to a subject in need of such treatment an effective amount of at least one substance which mediates relaxation of the anal sphincter. Compounds particularly indicated for the relaxation of the anal sphincter are those which are a source of nitric oxide or carbon monoxide.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Licchtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## TREATMENT OF ANORECTAL DISORDERS

The present invention relates to a new method of treating anorectal disorders in animals, and particularly in humans, by administering to a patient requiring such treatment specific compounds, as described hereafter. The invention is particularly concerned with the treatment of haemorrhoids and anal fissure in humans.

The treatment can be used with various anorectal disorders, including haemorrhoids, both internal and external, anal fissure, and generalised anal pain.

Various anal conditions such as haemorrhoids and fissure-in-ano, are associated with spasm of the internal anal sphincter. Up to the present time, no effective treatment is known for these conditions, other than various local surgical procedures. These surgical procedures involve stretching or cutting the anal sphincter in order to relieve the spasm. Also, topical ointments and creams are available, but these are not believed to have any direct influence on the anal conditions, but simply have analgesic or anti-inflammatory activity, in order to temporarily relieve the symptoms and pain. Sometimes these conditions occur when there is no measurable spasm. To date, no agent is known which can effectively relax the spasm of the anal sphincter muscle, or relax the muscle, and surgical treatment has been the only effective method of treatment of these conditions before the present time.

More specifically, haemorrhoids (also known as piles) are a varicose condition of the haemorrhoidal veins, causing painful swellings at the anus, as well as bleeding in some cases. With external haemorrhoids, the dilated veins form tumours on the outer side of the external sphincter, or are covered by the skin of the anal canal. Internal haemorrhoids occur when the swollen veins are beneath the mucous membrane within the sphincter. By the age of fifty, as many as 50% of people have haemorrhoids. The reason why haemorrhoids occur is not fully understood at present but may be caused by increased intra-abdominal pressure which may be caused by pregnancy, or straining in passing

stools, or alternatively it is believed that some hormonal influence may affect the rich network of blood vessels at the anus in such a way as to cause haemorrhoids to form.

The usual symptoms of haemorrhoids are bleeding, protrusion and pain. Ulcerated or thrombosed haemorrhoids are very painful. The pain caused by haemorrhoids can be severe or even incapacitating and methods of treatment of haemorrhoids have changed hardly at all in recent times. For severe pain, local anaesthetic can be applied topically and protruding internal haemorrhoids can be treated by rubber-band ligation. The usual therapy for haemorrhoids that cause only slight bleeding or minimal discomfort is warm sitz baths and stool softeners. Internal haemorrhoids that bleed persistently are treated by injection or by rubber-band ligation. Sometimes ointments and suppositories which are advertised widely for therapy of haemorrhoids can be used, but these, while of some assistance in relieving pain and discomfort, have no real therapeutic effect in curing the condition.

Anal fissure (fissure-in-ano) is a condition involving an acute longitudinal tear, or a chronic ovoid ulcer, in the stratified squamous epithelium of the anal canal. The exact causes of this condition is not known, though traumatic laceration from a hard or large stool may be involved. Fissures cause pain and bleeding with defecation. The pain typically occurs with or shortly following defecation, lasts for several hours, and then subsides until the next bowel movement.

It has been known for some time that the internal anal sphincter relaxes in response to rectal distension, which is known as "the rectanal inhibitory reflex". However little is known of the chemical mechanisms involved in this reflex. The nerves mediating the rectanal inhibitory reflex lie within the walls of the gut and are known as "enteric (intrinsic) inhibitory neurones". These neurones descend from the rectum to the internal anal sphincter and are known not to use classical neurotransmitter substances, such as acetylcholine or noradrenaline. These nerves are classified as non-adrenergic, non-cholinergic (NANC) nerves. Recently, a variety of substances such as nitric oxide (NO), and carbon monoxide (CO) are thought to act as neurotransmitters in the gastrointestinal

tract, and have been reported as being involved in the nerve mediated relaxation of the internal anal sphincter. In the body, nitric oxide is synthesised from L-arginine in a reaction catalysed by NO synthase. The NO synthase enzyme exhibits a high degree of substrate specificity, (for example NO is not produced from D-arginine), and is dependent  
5 on several cofactors including the presence of  $\text{Ca}^{2+}$  ions, calmodulin and reduced nicotinamide adenine dinucleotide phosphate. NO is very soluble, and diffuses rapidly in the body. It has a very short half life of only three seconds, and is inactivated by the formation of nitrate ( $\text{NO}_3^-$ ) after contact with the superoxide anion ( $\text{O}_2^-$ ). CO is produced from heme by the enzyme heme oxygenase.

10 Until the present invention, it had not been realised that substances which mediate either directly or indirectly relaxation of the anal sphincter may be used in the treatment of haemorrhoids, anal fissure, and other anorectal disorders.

15 The invention in one form therefore concerns a method of treating various anorectal conditions in an animal (including a human) which comprises administering to a subject in need of such treatment an effective amount of at least one substance which mediates relaxation of the anal sphincter. Preferably the substance modulates or influences NO or CO neurotransmitter ability. By this is meant that the substance has one or more of the  
20 effects of increasing the levels of NO or CO in the anorectal region, increasing the half life of endogenous NO or CO, increasing the affinity of NO or CO for their receptor in the anal sphincter, blocking inhibitors of NO or CO binding to their respective receptors, and increasing access of NO or CO to their receptor. It is to be understood that this invention is not limited to substances which modulate or influence NO or CO  
25 neurotransmitter ability. Rather, the invention extends to the use of any substance or combination of substances which mediate relaxation of the anal sphincter, which may hereinafter be referred to as anal sphincter relaxation substances.

30 Levels of NO or CO in the anorectal region may be increased by substances which are a source of NO or CO themselves (ie breakdown to form NO or CO in the presence of enzymes and/or other compounds in the body, or form NO or CO as a result of

activating compounds which form part of the composition) or which stimulate endogenous compounds (such as L-arginine or heme oxygenase) within the body to produce NO or CO for subsequent relaxation of the anal sphincter. Any substance which modulates or influences neurotransmitter ability in the manner described above may be utilised in this invention. Preferred substances which may be used according to the invention include nitrates, vasodilators, amino acids which break down to form NO, calcium channel blockers and the like.

Any nitrate compound or compound which breaks down in the body to form NO and which is non-toxic may be utilized according to this invention compounds which may be utilized include compounds which fall within the classes known as mononitrate, dinitrates, trinitrates, tetranitrates and the like. For example, nitrate compounds may be selected from isosorbide dinitrate, amyl nitrate, pentaerythritol tetranitrate, nitroglycerine (glyceryl nitrate) and the like. Nitroglycerine is particularly preferred for use in treating anorectal disorders such as haemorrhoids, anal fissure and similar conditions.

Vasodilator compounds, particularly those that influence NO neurotransmitter ability, can also be utilized in the invention, and these include hydralazine, and sodium or other salts of nitroprusside (nitroprusside being known as a donor of NO). Any vasodilator compound which is pharmaceutically acceptable and which relaxes the anal sphincter may be used in the invention. Examples of such compounds include alpreolol, amlodipine, atenolol, diltiazem, felodipine, limaprost, metoprolol, nicardipine, nifedipine, oxprenolol, prinadol, propranolol and the like.

Still other anal sphincter relaxation substances which may be used in the invention include acetyl choline, prostaglandins, vasoactive intestinal polypeptide, histamine, L-arginine, and the like. Compounds which stimulate heme oxygenase production within the body may also be utilized in the invention.

**SUBSTITUTE SHEET (Rule 26)**

Mixtures of more than one of the aforementioned active ingredients can also be utilized in the invention. For example, nitroglycerine can be utilized together with a long-acting nitrate, to allow longer lasting relief from haemorrhoid and other anorectal pain.

5 As mentioned previously, many anorectal conditions can be treated in accordance with the invention, including internal and external haemorrhoids, anal fissure, anal pain, and other, similar, conditions.

10 The active ingredients of the invention may be administered orally, topically, transdermally, parenterally such as by direct injection into the site of anorectal pain, by inhalation, transdermally, intrarectally, or to tissue surrounding the anus. Preferably, the active ingredients of the invention are administered directly to the anus. Non-oral administration routes are preferred for nitrate compounds such as nitroglycerine which may be inactivated by the liver. For topical administration, formulations such as ointments,  
15 creams, lotions and solutions are preferred. Long acting slow release dermal or other such device patches which release nitroglycerine or other active ingredients may be utilised. Rectal suppositories containing active ingredients as described are also contemplated by the invention.

20 The amount of active ingredient to be applied will vary, in accordance with the method of application chosen the activity of the active ingredient. For example, an active ingredient may be present in a composition in an amount from about 0.0001% w/w to 5% w/w or more. When nitroglycerine is the active ingredient, therapeutic compositions may contain the nitroglycerine in an amount of approximately 0.001 to 0.2% w/w, together  
25 with an hormone carriers component or other components. More preferably the amount of nitroglycerine present in a therapeutic composition is between about 0.1% and 0.2% w/w.

30 Composition or formulations for the administration of active agents according to the invention may be prepared with any suitable excipient or diluent as are well known in the art, such as are described in Remingtons Pharmaceutical Sciences (10th Edition, Mack

*Publishing Company, Philadelphia, USA*) which is incorporated herein by reference. Particularly preferred are those carriers and excipients well known in the art for anorectal administration, such as for the treatment of haemorrhoids, fissure and the like.

5           The formulations of the present invention may also include other ingredients which act as analgesics or anti-inflammatory agents. For example, in addition to the active ingredients, as described above, further analgesic and/or anti-inflammatory agents include benzocaine, lignocaine, xylocaine, cinchocaine, hydrocortisone, prednisolone, prednisone, adrenalin or methylhydroxybenzoate, are just some examples. Calcium channel blockers  
10       may also be further active ingredients. Preferred secondary ingredients include compounds which have previously been used to treat haemorrhoids, anal fissure, and other anal conditions. The amounts of the secondary ingredients present are chosen according to standard practice in the art.

15           This invention also relates to a method for the manufacture of a medicament for the treatment of anorectal conditions in an animal, which comprises admixing at least one substance which mediates relaxation of the anal sphincter with one or more pharmaceutically acceptable excipients or diluents.

20           The invention further relates to the use of one or more anal sphincter relaxation substance in the manufacture of a medicament for the treatment of anorectal conditions in animals.

25           In still another aspect, the invention relates to the use of one or more anal sphincter relaxation substances in the treatment of anorectal conditions in animals.

30           The invention is now described with reference to various examples. Whilst these examples relate to the use of nitroglycerine it is to be understood that the invention is not, of course, restricted to the use of this compound.



**EXAMPLE 1****Ointment Formulation**

5 A formulation was prepared containing glyceryl trinitrate (GTN - nitroglycerine) in an amount of 0.2% w/w, with the remainder of the formulation being soft yellow paraffin BP. A second formulation was made in the same manner, but with the glycerol trinitrate being present in an amount of 0.1% w/w, with the same ointment base.

**EXAMPLE 2****Treatment of Anal Fissure Condition**

10 A number of patients presenting to the Colorectal Unit attached to a large Sydney Hospital were entered into a trial. All the patients had symptomatic anal fissure, which would otherwise have required surgery. Subjects having anal fissure were chosen for the trial since the effects of the treatment are able to be monitored very easily.

15 Forty three patients were entered into a double-blind, randomised placebo-controlled trial. Subjects were randomly allocated either a 0.2% GTN paste, as described in Example 1, or otherwise a placebo containing no active ingredients, but identical in all other respects. Each subject underwent a detailed anorectal physiology study to test pressures within the anal canal. Each subject also filled in a pain score on a linear analogue scale, and progress in the healing of the fissure was monitored by two observers who were blinded to the form of treatment being given.

20 The twenty four patients who received GTN all experienced a successful chemical sphincterotomy resulting in a statistically significant improvement in pain, fissure grade and anal canal pressure compared with the placebo group of nineteen patients.

**EXAMPLE 3****Treatment of Haemorrhoids**

5 The 0.2% and 0.1% cream as described in Example 1 was tested with ten patients suffering from internal haemorrhoids. All patients exhibited haemorrhoid relief including reduction in haemorrhoid size, extent of bleeding, and less discomfort.

10 While the present invention is described with reference to various Examples, these Examples are not intended to be limiting on the invention, and other obvious modifications of the present invention can be utilized without departing from its broad scope as described previously.

The claims defining the invention are as follows:


- 5 1. A method for the treatment of anorectal conditions in animals which comprises administering to a subject in need of such treatment an effective amount of at least one substance which mediates the relaxation of the anal sphincter.
2. A method according to claim 1 wherein said substance is a source of nitric oxide or carbon monoxide.
- 10 3. A method according to claim 1 wherein said substance is a nitrate compound.
4. A method according to claim 3 wherein said nitrate compound is selected from isosorbide dinitrate, amyl nitrate, pentaerythritol, tetranitrate, and nitroglycerine.
- 15 5. A method according to claim 1 wherein said substance is nitroglycerine.
6. A method according to claim 1 wherein said substance is a vasodilator.
- 20 7. A method according to claim 6 wherein said vasodilator is selected from alpreolol, amlodipine, atenolol, diltiazem, felodipine, limaprost, metoprolol, nicardipine, nifedipine, oxprenolol, prinadol, and propranolol.
8. A method according to claim 1 wherein said substance is selected from acetyl choline, L-arginine, vasoactive intestinal polypeptide, histamine or a prostaglandin.
- 25 9. A method according to claim 1 wherein said substance is administered in association with an analgesic and/or anti-inflammatory agent.
- 30 10. A method according to any one of claims 1 to 9 wherein said substance is administered in association with one or more pharmaceutically acceptable carriers.

11. A method according to claim 1 wherein said substance is administered topically, subcutaneously, transdermally, parenterally, or interrectally.
12. A method according to claim 1 for the treatment of haemorrhoids.
- 5 13. A method according to claim 1 for the treatment of anal fissure.
14. A method according for the treatment of anorectal conditions in an animal which comprises administering to a subject in need of such treatment an effective amount of at least one substance which modulates nitric oxide or carbon monoxide neurotransmitter ability.
- 10 15. A method according to claim 14 wherein said substance is a source of nitric oxide or carbon monoxide.
- 15 16. A method according to claim 14 wherein said substance is a nitrate compound.
17. A method according to claim 14 wherein said nitrate compound is selected from isosorbide dinitrate, amyl nitrate, pentaerythritol tetranitrate, and nitroglycerine.
- 20 18. A method according to claim 14 wherein said substance is nitroglycerine.
19. A method according to claim 14 wherein said substance is a vasodilator.
- 25 20. A method according to claim 19 wherein said vasodilator is selected from alpreolol, amlodipine, atenolol, diltiazem, felodipine, limaprost, metaprolol, nicardipine, nifedipine, oxprenolol, prinadol, and propranolol.
- 30 21. A method according to claim 14 wherein said substance is selected from acetyl choline and L-arginine.

22. A method according to claim 14 wherein said substance is administered in association with an analgesic and/or anti-inflammatory agent.
- 5 22. A method according to 14 wherein said substance is administered in association with one or more pharmaceutically acceptable carriers.
23. A method according to claim 14 wherein said substance is administered topically, subcutaneously, transdermally, parenterally, or interrectally.
- 10 24. A method according to claim 14 for the treatment of haemorrhoids.
25. A method according to claim 14 for the treatment of anal fissure.
- 15 26. A method for the manufacture of a medicament for the treatment of anorectal conditions in an animal, which comprises admixing at least one substance which mediates relaxation of the anal sphincter with one or more pharmaceutically acceptable excipients or diluents.
- 20 27. A method according to claim 26 wherein said substance which mediates relaxation of the anal sphincter is selected from a compound according to any one of claims 2 through 8.
28. Use of one or more anal sphincter relaxation substances in the treatment of anorectal conditions in animals.
- 25 29. Use of one or more anal sphincter relaxation substances in the manufacture of a medicament for the treatment of anorectal conditions in animals.
- 30 30. An agent for the treatment of anorectal conditions in animals which comprises at least one substance which mediates the relaxation of the anal sphincter.

31. An agent according to claim 30 wherein said substance which mediates the relaxation of the anal sphincter is a substance according to any one of claims 1 through 8.

**SUBSTITUTE SHEET (Rule 26)**

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> Int. Cl. <sup>6</sup> A61K 31/21, 31/04, 31/345  According to International Patent Classification (IPC) or to both national classification and IPC					
<b>B. FIELDS SEARCHED</b>  Minimum documentation searched (classification system followed by classification symbols) IPC : A61K 31/21, 31/04, 31/345  Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  Electronic data base consulted during the international search (name of data base, and where practicable, search terms used) WPAT: A61K 31/04, A61K 31/345, NITROGLYCERINE, AMYL NITRATE, PENTAERYTHRITOL, TETRANITRATE CAS: NITRATE AND ANORECTAL OR HAEMORRHOIDS OR PILES					
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>					
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.			
X	Derwent Primary Accession No. 45741A/25, Class B06 ZA 7701-135 (PRINSLOO JJ) 12 April 1978 (12.04.78) see abstract	1-3, 11, 12, 14-16, 22-24, 26-31			
A	US,A 3419571 (DI CARLO) 31 December 1968 (31.12.68) entire document	1-31			
<div style="display: flex; justify-content: space-between;"> <span><input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C.</span> <span><input checked="" type="checkbox"/> See patent family annex.</span> </div>					
<table style="width: 100%; border: none;"> <tr> <td style="width: 33%; vertical-align: top;">           * Special categories of cited documents :            "A" document defining the general state of the art which is not considered to be of particular relevance            "E" earlier document but published on or after the international filing date            "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)            "O" document referring to an oral disclosure, use, exhibition or other means            "P" document published prior to the international filing date but later than the priority date claimed         </td> <td style="width: 33%; vertical-align: top;">           "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle of theory underlying the invention            "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone            "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art            "&amp;" document member of the same patent family         </td> <td style="width: 33%;"></td> </tr> </table>			* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle of theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family	
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle of theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family				
Date of the actual completion of the international search 18 October 1994 (18.10.94)	Date of mailing of the international search report <b>8 Nov 1994 (8.11.94)</b>				
Name and mailing address of the ISA/AU AUSTRALIAN INDUSTRIAL PROPERTY ORGANISATION PO BOX 200 WODEN ACT 2606 AUSTRALIA  Facsimile No. 06 2853929	Authorized officer   <b>J. PULVIRENTI</b>  Telephone No. (06) 2832261				

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate of the relevant passages	Relevant to Claim No.
A	US,A, 4450175 (WARSHAW) 22 May 1984 (22.05.84) entire document	1-31
A	AU,A, 61158/90 (KEY PHARMACEUTICALS, INC) 7 February 1991 (07.02.91) entire document	1-31



## INTERNATIONAL SEARCH

Information on patent family members

**PCT/AU 94/00487**

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report			Patent Family Member				
ZA	7701-135						
US	3419571	FR	6487				
US	4450175						
AU	3688075	DE WO	3688075 8703490	EP	250542	US	4764381

THIS PAGE BLANK (USPTO)